Back to top
more

Adaptimmune Therapeutics (ADAP)

(Delayed Data from NSDQ)

$1.17 USD

1.17
429,171

+0.05 (4.46%)

Updated May 13, 2024 04:00 PM ET

After-Market: $1.17 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study

by Zacks Equity Research

IO Biotech (IOBT) falls 25% despite achieving the clinical milestone of enrolling 225 patients in the advanced melanoma study evaluating the IO102-IO103/Keytruda combo.

Gracell Biotechnologies (GRCL) Surges 62% in a Week: Here's Why

by Zacks Equity Research

Shares of Gracell (GRCL) increase after it reported positive data from two clinical studies, which evaluated its experimental CAR T cell therapy drug in patients with B-cell non-hodgkin's lymphoma and multiple myeloma.

First Wave (FWBI) Surges 33% on Finishing Enrolment in CF Study

by Zacks Equity Research

First Wave (FWBI) completes enrolment in a mid-stage study evaluating its investigational oral capsule in patients with cystic fibrosis. Topline data from the study is expected next month.

Acadia (ACAD) to Begin Study on ACP-101 for Hyperphagia in PWS

by Zacks Equity Research

Acadia (ACAD) is set to begin a pivotal study evaluating a new developmental candidate, ACP-101, in the treatment of hyperphagia associated with Prader-Willi syndrome.

AstraZeneca (AZN) Breast Cancer Combo Drug Gets Priority Review

by Zacks Equity Research

The FDA grants priority review status to AstraZeneca's (AZN) capivasertib/Faslodex combination for the treatment of adult patients with HR-positive, HER2-negative locally advanced breast cancer.

Editas (EDIT) Posts Upbeat Initial Data From SCD & TDT Studies

by Zacks Equity Research

Editas (EDIT) announces positive preliminary safety and efficacy data from patients treated with its lead drug, EDIT-301, in the RUBY and EdiTHAL studies to treat SCD and TDT, respectively.

AstraZeneca (AZN) & Quell to Co-Develop Autoimmune Cell Therapies

by Zacks Equity Research

AstraZeneca (AZN) enters into a collaboration agreement with Quell Therapeutics to co-develop novel cell therapy options in major autoimmune indications for an upfront payment of $85 million.

Merck's (MRK) Keytruda for Liver Cancer to Undergo FDA Review

by Zacks Equity Research

FDA accepts Merck's (MRK) supplemental biologics license application for Keytruda plus chemotherapy for the treatment of patients with first-line advanced or metastatic biliary tract cancer.

Rocket (RCKT) Heart Disease Drug Gets Fast Track & Orphan Drug Tag

by Zacks Equity Research

The FDA grants fast track tag and orphan drug designation to Rocket's (RCKT) investigational gene therapy candidate, RP-A601, for cardiac indication. The stock gains 2.3% following the news.

Dr. Reddy's (RDY) Meets Goals in Actemra Biosimilar Study

by Zacks Equity Research

Dr. Reddy's (RDY) announces meeting primary and secondary endpoints in the phase I study of its proposed tocilizumab biosimilar for the treatment of rheumatoid arthritis in adults.

Novo Nordisk (NVO) Gears Up to Acquire BIOCORP for 154M Euros

by Zacks Equity Research

Novo Nordisk (NVO) enters into negotiations to acquire a majority stake in BIOCORP, followed by a tender offer to acquire all remaining shares in BIOCORP for a total equity value of 154 million Euros.

Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study

by Zacks Equity Research

Bristol Myers (BMY) reports encouraging four-year clinical efficacy results from its lung cancer study upon treatment with the combination immunotherapy of Opdivo plus Yervoy.

Down -22.38% in 4 Weeks, Here's Why You Should You Buy the Dip in Adaptimmune Therapeutics PLC (ADAP)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Adaptimmune Therapeutics PLC (ADAP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Perrigo (PRGO) Tops Q1 Earnings & Sales, Reiterates '23 View

by Zacks Equity Research

Perrigo (PRGO) reports encouraging first-quarter 2023 results. Management reaffirms the financial guidance for 2023. The company's current CEO announces plans to retire by the end of July.

Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q1

by Zacks Equity Research

Karuna Therapeutics (KRTX) reports encouraging first-quarter 2023 results. The company beats estimates for earnings and sales.

Agios (AGIO) Q1 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) reports encouraging first-quarter results, beating estimates for earnings and sales.

Zacks.com featured highlights Sweetgreen, Adaptimmune Therapeutics, Owl Rock Capital, MACOM Technology Solutions and Equity Commonwealth

by Zacks Equity Research

Sweetgreen, Adaptimmune Therapeutics, Owl Rock Capital, MACOM Technology Solutions and Equity Commonwealth have been highlighted in this Screen of The Week article.

Allogene's (ALLO) Q1 Loss Wider Than Expected, Sales Miss

by Zacks Equity Research

Allogene's (ALLO) first-quarter results miss both earnings and sales estimates.

Sanghamitra Saha headshot

Forget Bargain Hunting, Buy 5 Stocks With Rising P/E

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include Sweetgreen (SG), Adaptimmune Therapeutics (ADAP), Owl Rock Capital (ORCC), MACOM Technology Solutions (MTSI) and Equity Commonwealth (EQC).

Adaptimmune (ADAP) Up 7%, Gets T-Cell Programs Rights From GSK

by Zacks Equity Research

Adaptimmune Therapeutics (ADAP) enters into a transition deal with GSK to regain rights to its proprietary T-cell therapy programs. Shares of the company surges 7% following the news.

Mesa Labs and Eldorado Gold have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Mesa Labs and Eldorado Gold are part of the Zacks Bull and Bear of the Day article.

DBV (DBVT) Up as FDA Lifts Partial Hold on Peanut Allergy Study

by Zacks Equity Research

The FDA lifts the partial clinical hold on DBV Technologies' (DVBT) phase III VITESSE study of a modified Viaskin Peanut patch in peanut-allergic children aged four to seven years. Stock rises.

Sundeep Ganoria headshot

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

by Sundeep Ganoria

We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.

New Strong Sell Stocks for April 26th

by Zacks Equity Research

ANIK, ALIM, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2022

New Strong Sell Stocks for April 22nd

by Zacks Equity Research

BBBY, CLGN, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 22, 2022